srch

250 rader · Read the full presentation. 1623316840. June 10, 2021. Avapritinib. 2021 Society for …

11.04.2021 · -- BLU-263 was well-tolerated across all doses tested in Phase 1 healthy volunteer trial, supporting plans to initiate Phase 2/3 HARBOR trial in non-advanced SM in mid-2021 -- -- …

Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in ...

BLU 263, is a next-generation orally available, tyrosine kinase inhibitor (KIT) being developed by Blueprint Medicines for the treatment of indolent ...

11.01.2021 · Positive top-line results from a Phase 1 trial in healthy volunteers showed BLU-263 was well-tolerated across a range of single- and multiple-ascending doses predicted to potently inhibit D816V mutant KIT, the underlying SM disease driver.

Blueprint Medicines submitted an investigational new drug (IND) application to the FDA for BLU-263, a next-generation KIT inhibitor, ...

Blueprint Medicines Reports Second Quarter 2021 Financial Results - read ... NSCLC and Phase 2/3 HARBOR trial of BLU-263 in non-advanced SM ...

This research was funded by Blueprint Medicines Corporation. Blueprint Medicines reviewed and provided feedback on the poster. The authors had ...

Blueprint Medicines Corporation. Information provided by (Responsible Party): ... Patients will be randomized 2:1 to BLU-263:placebo.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

BLU-263 is an investigational, potent, and selective oral small molecule inhibitor of KIT with sub-nanomolar potency against D816V-mutant KIT. Systemic mastocytosis is driven by the KIT D816V mutation in approximately 95% of cases and is vulnerable to KIT D816V inhibition.

02.06.2021 · Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with BLU-263 in an open-label fashion following completion of the earlier Part. Part M will enroll patients with monoclonal mast cell activation syndrome (mMCAS). The study also includes PK groups that may enroll patients with ISM. Study Design Go to

30.09.2019 · Blueprint Medicines plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for BLU-263 for indolent SM in the first half of 2020.

Blueprint Medicines estimates about 30% of patients with hepatocellular carcinoma (HCC) ... BLU-263 BLU-263 is a next-generation KIT D816V inhibitor developed based on insights from the avapritinib program..BLU-263 was designed to potently inhibit D816V mutant KIT with minimal central nervous system penetration.

It is investigating fisogatinib for the treatment of advanced hepatocellular carcinoma; BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines is ...

The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, ...

19 rader · 01.12.2021 · Blueprint Medicines and Roche have co-exclusive rights to develop and …

1Blueprint Medicines Corporation, Cambridge, Massachusetts, USA; 2Celerion Inc, Lincoln, Nebraska, USA Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers 1296P Background Conclusions • In healthy volunteers, BLU-263, a next-generation investigational KIT D816V inhibitor, was safe at all doses tested